NCT01677013

Autologous Bone Marrow Mononuclear Cell Transplantation in Treating Type 2 Diabetes Mellitus

Efficacy of Autologous Bone Marrow Mononuclear Cell Transplantation in Treating Selective Type 2 Diabetes Mellitus

• Status: Completed
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 1,026 (actual)
• Sponsor: Peking University Aerospace Center Hospital · Academic / Other
• Sex: All
• Age: 30 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The study is aimed to evaluate the safety and efficiency of autologous bone marrow mononuclear cell transplantation in treating selective patients with type 2 Diabetes Mellitus. We hypothesized that autologous bone marrow stem cell transplantation would promote β-cells regeneration by directly differentiated from the transplanted BMMCs or stimulate local stem cells regeneration and thus decrease or eliminate the need of exogenous insulin and improve β-cells function.

Detailed description

To study the safety and efficacy of bone marrow mononuclear cell transplantation in type 2 diabetics. According to the intervention and baseline characteristics, patients are divided into 4 arms.

Conditions

• Type 2 Diabetes Mellitus

Interventions

Type	Name	Description
OTHER	BMMCT	Bone marrow mononuclear cell transplantation via selective catheterization

Timeline

• Start date: 2011-05-01
• Primary completion: 2015-05-01
• Completion: 2017-07-01
• First posted: 2012-08-31
• Last updated: 2017-10-03

Locations

1 site across 1 country: China